Cardiac AI: Bending the Cost Curve, Reducing Claims

The hype around AI in healthcare always points to the clinical trial data, better diagnostic accuracy, faster treatment, improved patient outcomes. And while that’s all necessary for getting through the FDA and into a hospital, it doesn’t answer the one question investors keep asking: “What AI platforms show measurable reductions in cardiovascular claims?” This is about the money. It’s about the tangible financial impact that lets a company build a sustainable business. For VCs and institutional investors, a great algorithm isn’t enough. The real differentiator is its proven ability to bend the cost curve by cutting down what payers have to shell out.

Rethinking ROI: From Clinical Efficacy to Claims Reduction

We’ve gotten into a bad habit of looking at clinical trial endpoints as a direct proxy for financial success in digital health. That perspective is understandable, but it completely misses the brutal, complex journey from a validated algorithm to actual, real-world claims reduction. So your AI makes a diagnosis 20% faster, that’s impressive clinically, but if that speed doesn’t lead to fewer hospitalizations, lower readmission rates, or cheaper treatment pathways, its ROI is pure fantasy. The focus has to shift to an evidence-first model where the “evidence” isn’t a percentage in a study but hard claims and reimbursement data from huge databases. That proof has to come before the investment, not after. We just saw this play out with Olive AI, a company that pulled in over $900 million from big names like Tiger Global only to shut down completely. It’s a stark reminder that investors have to dig into the economic engine of an AI solution, not just its tech specs.

Case Studies in Claims Impact: Viz.ai and Tempus AI

Two different models for cutting cardiovascular claims are emerging: one that hits acute care pathways head-on and another that works on optimizing long-term treatment. Viz.ai, valued at $1.2 billion after its $100 million Series D with backers like Tiger Global, is a prime example of the first model. Its AI platform coordinates care for large vessel occlusion (LVO) strokes, dramatically speeding up the time-to-treatment. Of course there are clinical benefits like better neurological outcomes, but the money part is what gets an investor’s attention. By getting a patient from stroke onset to a thrombectomy procedure faster, Viz.ai short-circuits the massive long-term costs that come with severe disability and years of rehab. Even more directly, the platform makes patient transfers and hospital resource allocation more efficient, which means better use of expensive assets like interventional suites. The real clincher? Viz.ai successfully got New Technology Add-on Payment (NTAP) status from CMS for some of its tech, giving hospitals a direct financial incentive to use it CMS NTAP documentation for Viz.ai. That reimbursement pathway was the ultimate validation, proving its economic value to both payers and providers by preventing the most expensive stroke outcomes. Then you have a company like Tempus AI, which went public on NASDAQ in June 2024 at a $6.1 billion valuation and pulled in another $460 million post-IPO in July 2026. It operates in precision medicine, and while its main focus has been oncology, the model is a perfect parallel for cardiovascular disease. Tempus uses massive genomic and clinical datasets to guide personalized treatment. For cardiology, the application is obvious: identify which patients will actually respond to a specific, high-cost therapy and which ones won’t, avoiding ineffective treatments. By giving doctors a data-backed reason to choose one pathway over another, Tempus helps cut down on the “trial-and-error” prescribing that runs up bills through adverse reactions and wasted time on therapies that don’t work. The company’s own metrics are built around tracking how its reports change what doctors do and how patients fare as a result, which is where the cost savings come from Peer-reviewed study on Tempus AI clinical utility. The claims reduction here is less direct but potentially much larger, coming from smarter treatment selection that prevents costly complications down the road.

An Actionable Framework for Auditing Vendor Claims Data

So how do you, the investor, actually figure out if an AI platform is for real? You have to run a tough, evidence-first audit. Here’s a framework: 1. Demand Peer-Reviewed Health Economic Studies: Don’t accept a vendor’s slick white paper. You need to see research published in a real journal that analyzes huge claims databases from sources like Medicare or commercial payers. The study must explicitly show a drop in specific claims, inpatient admissions, readmissions, procedure costs, that can be tied directly to their AI. Our own research network, Healthcare AI ROI Research, uses cases like Hello Heart’s peer-reviewed $1,800 per-member savings and 47% inpatient reduction as the gold standard for this kind of proof. 2. Scrutinize Reimbursement Pathways and Codes: If there’s no clear way for a hospital or clinic to get paid for using the tech, it’s a non-starter. Ask about their reimbursement strategy. Is it eligible for NTAP in the inpatient setting? Are there specific CPT codes (Category I or III) for outpatient use AMA CPT code guidelines? A blank stare on this question means they face a massive barrier to adoption and won’t have any sustained impact on claims. 3. Analyze Real-World Evidence (RWE) from Diverse Populations: A clinical trial is a controlled bubble. You need to see RWE showing the AI works and saves money across different kinds of patients and hospital systems. This is your defense against problems with algorithmic drift and the risk that the tool just doesn’t work outside of a specific test environment. 4. Deconstruct the “Why” Behind Claim Reductions: Make them explain exactly how the AI saves money. Is it by preventing a specific adverse event? Making ORs more efficient? Getting patients to take their meds? Each claim needs a clear mechanism supported by data. If they say they reduce the length of an inpatient stay, your next question should be, “Okay, show me the data on bed-days saved and the exact cost reduction per patient.” 5. Beware of “Zombie Companies”: The digital health market is littered with startups that get some seed funding and a 510(k) clearance but never achieve real commercial use or prove they can lower costs. These “zombie companies” are just taking up space. Your due diligence should zero in on companies that can show you they’ve deployed at scale and have documented financial results that go far beyond a small pilot program.

Methodology Note: The Power of Database Analysis

At Healthcare AI ROI Research, our entire analytical approach is built on one thing: digging into large-scale, de-identified claims databases. It’s the only way to get an unvarnished look at financial impact, completely free of the self-serving bias you find in small, vendor-funded studies. When we analyze millions of patient encounters and the associated claims, we can spot statistically significant cost reductions that are directly linked to a specific AI tool. Our process involves:

• Cohort Analysis: We compare the costs and outcomes for patients who were exposed to the AI against a control group that wasn’t.
• Propensity Score Matching: This is a statistical method we use to make sure we’re comparing apples to apples, accounting for other factors that could influence the results.
• Longitudinal Tracking: We don’t just look at a snapshot in time. We track cost trends over long periods to see if the savings are real and if they last. This method prioritizes cold, hard financial data over a company’s hopeful projections, giving investors the clarity they need. The goal is to change how investment works in this space: stop chasing clinical novelty and start backing platforms with sustainable economic models proven by real-world reimbursement and claims data.